Potential effect on mortality statistics, England and Wales. Off National Statistics Statistical Bull. 2012. Albertsen Computer, Walters S, Hanley JA. A comparison of reason for death determination in guys previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol. 2000;163(two):5193. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer sufferers and in a comparison nonprostate cancer cohort. J Natl Cancer Inst. 2000;92(eight):6131. M inen T, Karhunen P, Aro J, Lahtela J, M tt en L, Auvinen A. Assessment of causes of death in a prostate cancer screening trial. Int J Cancer. 2008;122(two):413. Gilbert R, Martin RM, Donovan J, Lane JA, Hamdy F, Neal DE, et al. Misclassification of outcome in case-control research: procedures for sensitivity evaluation. Stat Strategies Med Res. in press. Black WC, Haggstrom DA, Gilbert Welch H. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst. 2002;94(3):1673. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the G eborg randomised population-based prostatecancer screening trial. Lancet Oncol. 2010;11(8):7252. Robinson MH, Rodrigues VC, Hardcastle JD, Chamberlain JO, Mangham CM, Moss SM.GSK-3 beta Protein supplier Faecal occult blood screening for colorectal cancer at Nottingham: particulars of the verification method. J Med Screen. 2000;7(two):97. Marcus PM, Gareen IF, Miller AB, Rosenbaum J, Keating K, Aberle DR, et al. The national lung screening Trial’s endpoint verification approach: figuring out the cause of death. Contemp Clin Trials. 2011;32(six):8340. G zsche Computer, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2009;four:1. Turner E, Metcalfe C, Donovan J, Noble S, Sterne J, Lane J, et al. Style and preliminary recruitment final results from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). Br J Cancer. 2014;110(12):28296. Prostate Cancer Danger Management Programme. ://cancerscreening.nhs. uk/prostate/informationpack.html. Lane J, Hamdy F, Martin R, Turner E, Neal D, Donovan J. Latest outcomes in the UK trials evaluating prostate cancer screening and treatment: the CAP and Shield research. Eur J Cancer. 2010;46(17):309501. Boutron I, Estellat C, Ravaud P. A review of blinding in randomized controlled trials located outcomes inconsistent and questionable. J Clin Epidemiol. 2005;58(12):1220. Hr jartsson A, Forfang E, Haahr M, Als-Nielsen B, Brorson S. Blinded trials taken for the test: an analysis of randomized clinical trials that report tests for the good results of blinding.Hemoglobin subunit theta-1/HBQ1 Protein MedChemExpress Int J Epidemiol.PMID:28739548 2007;36(three):6543. Doria-Rose VP, Marcus PM, Miller AB, Bergstralh EJ, Mandel JS, Tockman MS, et al. Does the supply of death facts have an effect on cancer screening efficacy final results A study on the use of mortality evaluation versus death certificates in four randomized trials. Clin Trials. 2010;7(1):697. Barry MJ, Andriole GL, Culkin DJ, Fox SH, Jones KM, Carlyle MH, et al. Ascertaining cause of death among guys within the prostate cancer intervention versus observation trial. Clin Trials. 2013;10(six):9074. Schulz KF, Altman DG, Moher D, Fergusson D. CONSORT 2010 changes and testing blindness in RCTs. Lancet. 2010;375(9721):1144. Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet. 2003;361(9363):1122.doi:10.1186/1471-2288-15-6 Cite this article as: Williams et al.: Standardisation of info submitted to an endpoint committee for reason for death assignment in a cancer screening trial l.